Biologics Market Size and Forecast (2021 – 2031)

Cancer Segment, by Application to Account Larger Share in Biologics Market during 2023–2031

According to our new research study on “Biologics Market Forecast to 2031 – Global Analysis – by Product, Application, Source, Manufacturing, and Geography,” the market was valued at US$ 469.2 billion in 2023 and is projected to reach US$ 1,793.9 billion by 2031; it is expected to register a CAGR of 18.2% during 2023–2031. The market growth is attributed to the increasing cases of chronic diseases and the preference for outsourcing manufacturing operations. However, the stringent regulations and high drug development costs hinder the growth of the market.

Biologics manufacturing is a complex process whose success depends on the proper execution and monitoring of all operations. The manufacturing facilities need trained personnel with the technical knowledge of bioprocessing and process engineering. Managing the attempts to reach the first clinical trial using a manual and open manufacturing method and then building a more commercially suitable process can be tricky for an experienced team. Thus, manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization operations. CDMOs provide product development, clinical trial support, manufacturing, and commercialization services to biologics companies on a contract basis. Partnering with a CDMO enables scalability and access to technical expertise without overhead costs, along with higher speed to market and greater cost efficiencies for biologics manufacturers. In April 2022, ThermoGenesis established its own CDMO facility in California, US, to provide CDMO services to cell and gene therapy manufacturers. Using its expertise, the company focuses on manufacturing chimeric antigen receptor-T cell (CAR-T cell), T-cell receptor (TCR), tumor-infiltrating leukocyte (TIL), natural killer cell (NK), iPSC, and mesenchymal stem cell (MSC). Outsourcing biologics manufacturing to CDMOs proves cost-effective for manufacturers. Additionally, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing biologics. Thus, the surging preference for outsourcing biologics manufacturing operations to CDMOs fuels the biologics market growth.

Based on product, the biologics market is divided into monoclonal antibodies, vaccines, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023, and it is further likely to register the highest CAGR during 2023–2031.

By application, the market is segmented into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest share of the market in 2023, and it is anticipated to register the highest CAGR during 2023–2031. As per the World Health Organization (WHO), the count of new cancer cases reached ~20 million in the world while ~9.7 million people succumbed to death due to the disease in 2022; the new diagnoses included 9.3 million men and 8.8 million women. Additionally, breast and lung cancers were the most common cancer types, accounting for 12.5% and 12.2% of the total diagnoses, respectively. Therefore, oncology, an area with high unmet medical needs, has received massive attention for the need for new treatment options. Over 1,500 ongoing clinical trials for cell and gene therapies have been registered with ClinicalTrials.gov, and approximately 60% of these are for cancer treatment. Moreover, 90% of all total clinical trials are the Phase 1 and 2 trials. In May 2024, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

In terms of manufacturing, the market is bifurcated into outsourced and in-house. The outsourced segment held a larger share of the market in 2023; it is estimated to register a higher CAGR during 2023–2031.

In terms of source, the biologics market is segmented into mammalian and microbial. The microbial segment held a larger market share in 2023. The mammalian is estimated to record a faster CAGR during 2023–2031. In production, cultured mammalian cells have become the predominant expression systems due to their ability to complete the posttranslational modifications that are necessary for drug safety and efficacy. The mammalian cell culture production processes have evolved dramatically due to improvements in both volumetric and specific outcomes. Over the past decade, cells derived from animals, especially rodents, have become primary vectors for producing biologics. Mammalian cell culture is employed for the synthesis of vaccines and various other proteins for their clinical applications, including the treatment of cancer, genetic diseases, and other ailments. The production of vaccines and therapeutic proteins through mammalian cells requires viral infection and genetic engineering stages for the transfer of the gene of interest in the expression systems.

AbbVie Inc.; Pfizer Inc.; Samsung Biologics; ADMA Biologics, Inc.; WuXi Biologics; Catalent, Inc; AGC Biologics; AstraZeneca; Amgen Inc.; Nitto Avecia; and Quality Assistance SA are among the leading companies operating in the global biologics market.

Companies operating in the biologics market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the biologics market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall biologics market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the biologics market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the biologics market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth market trends and outlook coupled with the factors driving the biologics market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The the Reporting Teams Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. Biologics Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Biologics Market – Key Market Dynamics
5.1 Biologics Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Increasing Prevalence of Chronic Diseases
5.2.2 Preference for Outsourcing Manufacturing Operations
5.3 Market Restraints
5.3.1 High Cost of Biologics
5.4 Market Opportunities
5.4.1 Evolution of Biotechnology in Developing Regions
5.5 Future Trends
5.5.1 Strategic Initiatives by Companies
5.6 Impact of Drivers and Restraints:
6. Biologics Market – Global Market Analysis
6.1 Biologics Market Revenue (US$ Million), 2021–2031
6.2 Biologics Market Forecast Analysis
7. Biologics Market Analysis – by Product
7.1 Monoclonal Antibodies
7.1.1 Overview
7.1.2 Monoclonal Antibodies: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Vaccine
7.2.1 Overview
7.2.2 Vaccine: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Recombinant Hormones/Proteins
7.3.1 Overview
7.3.2 Recombinant Hormones/Proteins: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Cell and Gene Therapy
7.4.1 Overview
7.4.2 Cell and Gene Therapy: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
8. Biologics Market Analysis – by Application
8.1 Cancer
8.1.1 Overview
8.1.2 Cancer: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Autoimmune Diseases
8.3.1 Overview
8.3.2 Autoimmune Diseases: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
9. Biologics Market Analysis – by Source
9.1 Mammalian
9.1.1 Overview
9.1.2 Mammalian: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Microbial
9.2.1 Overview
9.2.2 Microbial: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
10. Biologics Market Analysis – by Manufacturing
10.1 Outsourced
10.1.1 Overview
10.1.2 Outsourced: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
10.2 In-house
10.2.1 Overview
10.2.2 In-house: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11. Biologics Market – Geographical Analysis
11.1 Overview
11.2 North America
11.2.1 North America Biologics Market Overview
11.2.2 North America: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3 North America: Biologics Market Breakdown, by Product
11.2.3.1 North America: Biologics Market – Revenue and Forecast Analysis – by Product
11.2.4 North America: Biologics Market Breakdown, by Application
11.2.4.1 North America: Biologics Market – Revenue and Forecast Analysis – by Application
11.2.5 North America: Biologics Market Breakdown, by Source
11.2.5.1 North America: Biologics Market – Revenue and Forecast Analysis – by Source
11.2.6 North America: Biologics Market Breakdown, by Manufacturing
11.2.6.1 North America: Biologics Market – Revenue and Forecast Analysis – by Manufacturing
11.2.7 North America: Biologics Market – Revenue and Forecast Analysis – by Country
11.2.7.1 North America: Biologics Market – Revenue and Forecast Analysis – by Country
11.2.7.2 United States: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.2.1 United States: Biologics Market Breakdown, by Product
11.2.7.2.2 United States: Biologics Market Breakdown, by Application
11.2.7.2.3 United States: Biologics Market Breakdown, by Source
11.2.7.2.4 United States: Biologics Market Breakdown, by Manufacturing
11.2.7.3 Canada: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.3.1 Canada: Biologics Market Breakdown, by Product
11.2.7.3.2 Canada: Biologics Market Breakdown, by Application
11.2.7.3.3 Canada: Biologics Market Breakdown, by Source
11.2.7.3.4 Canada: Biologics Market Breakdown, by Manufacturing
11.2.7.4 Mexico: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.4.1 Mexico: Biologics Market Breakdown, by Product
11.2.7.4.2 Mexico: Biologics Market Breakdown, by Application
11.2.7.4.3 Mexico: Biologics Market Breakdown, by Source
11.2.7.4.4 Mexico: Biologics Market Breakdown, by Manufacturing
11.3 Europe
11.3.1 Europe Biologics Market Overview
11.3.2 Europe: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3 Europe: Biologics Market Breakdown, by Product
11.3.3.1 Europe: Biologics Market – Revenue and Forecast Analysis – by Product
11.3.4 Europe: Biologics Market Breakdown, by Application
11.3.4.1 Europe: Biologics Market – Revenue and Forecast Analysis – by Application
11.3.5 Europe: Biologics Market Breakdown, by Source
11.3.5.1 Europe: Biologics Market – Revenue and Forecast Analysis – by Source
11.3.6 Europe: Biologics Market Breakdown, by Manufacturing
11.3.6.1 Europe: Biologics Market – Revenue and Forecast Analysis – by Manufacturing
11.3.7 Europe: Biologics Market – Revenue and Forecast Analysis – by Country
11.3.7.1 Europe: Biologics Market – Revenue and Forecast Analysis – by Country
11.3.7.2 Germany: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.2.1 Germany: Biologics Market Breakdown, by Product
11.3.7.2.2 Germany: Biologics Market Breakdown, by Application
11.3.7.2.3 Germany: Biologics Market Breakdown, by Source
11.3.7.2.4 Germany: Biologics Market Breakdown, by Manufacturing
11.3.7.3 United Kingdom: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.3.1 United Kingdom: Biologics Market Breakdown, by Product
11.3.7.3.2 United Kingdom: Biologics Market Breakdown, by Application
11.3.7.3.3 United Kingdom: Biologics Market Breakdown, by Source
11.3.7.3.4 United Kingdom: Biologics Market Breakdown, by Manufacturing
11.3.7.4 Italy: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.4.1 Italy: Biologics Market Breakdown, by Product
11.3.7.4.2 Italy: Biologics Market Breakdown, by Application
11.3.7.4.3 Italy: Biologics Market Breakdown, by Source
11.3.7.4.4 Italy: Biologics Market Breakdown, by Manufacturing
11.3.7.5 France: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.5.1 France: Biologics Market Breakdown, by Product
11.3.7.5.2 France: Biologics Market Breakdown, by Application
11.3.7.5.3 France: Biologics Market Breakdown, by Source
11.3.7.5.4 France: Biologics Market Breakdown, by Manufacturing
11.3.7.6 Spain: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.6.1 Spain: Biologics Market Breakdown, by Product
11.3.7.6.2 Spain: Biologics Market Breakdown, by Application
11.3.7.6.3 Spain: Biologics Market Breakdown, by Source
11.3.7.6.4 Spain: Biologics Market Breakdown, by Manufacturing
11.3.7.7 Rest of Europe: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.7.1 Rest of Europe: Biologics Market Breakdown, by Product
11.3.7.7.2 Rest of Europe: Biologics Market Breakdown, by Application
11.3.7.7.3 Rest of Europe: Biologics Market Breakdown, by Source
11.3.7.7.4 Rest of Europe: Biologics Market Breakdown, by Manufacturing
11.4 Asia Pacific
11.4.1 Asia Pacific Biologics Market Overview
11.4.2 Asia Pacific: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3 Asia Pacific: Biologics Market Breakdown, by Product
11.4.3.1 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Product
11.4.4 Asia Pacific: Biologics Market Breakdown, by Application
11.4.4.1 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Application
11.4.5 Asia Pacific: Biologics Market Breakdown, by Source
11.4.5.1 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Source
11.4.6 Asia Pacific: Biologics Market Breakdown, by Manufacturing
11.4.6.1 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Manufacturing
11.4.7 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Country
11.4.7.1 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Country
11.4.7.2 China: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.2.1 China: Biologics Market Breakdown, by Product
11.4.7.2.2 China: Biologics Market Breakdown, by Application
11.4.7.2.3 China: Biologics Market Breakdown, by Source
11.4.7.2.4 China: Biologics Market Breakdown, by Manufacturing
11.4.7.3 India: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.3.1 India: Biologics Market Breakdown, by Product
11.4.7.3.2 India: Biologics Market Breakdown, by Application
11.4.7.3.3 India: Biologics Market Breakdown, by Source
11.4.7.3.4 India: Biologics Market Breakdown, by Manufacturing
11.4.7.4 Japan: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.4.1 Japan: Biologics Market Breakdown, by Product
11.4.7.4.2 Japan: Biologics Market Breakdown, by Application
11.4.7.4.3 Japan: Biologics Market Breakdown, by Source
11.4.7.4.4 Japan: Biologics Market Breakdown, by Manufacturing
11.4.7.5 South Korea: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.5.1 South Korea: Biologics Market Breakdown, by Product
11.4.7.5.2 South Korea: Biologics Market Breakdown, by Application
11.4.7.5.3 South Korea: Biologics Market Breakdown, by Source
11.4.7.5.4 South Korea: Biologics Market Breakdown, by Manufacturing
11.4.7.6 Australia: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.6.1 Australia: Biologics Market Breakdown, by Product
11.4.7.6.2 Australia: Biologics Market Breakdown, by Application
11.4.7.6.3 Australia: Biologics Market Breakdown, by Source
11.4.7.6.4 Australia: Biologics Market Breakdown, by Manufacturing
11.4.7.7 Rest of APAC: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.7.1 Rest of APAC: Biologics Market Breakdown, by Product
11.4.7.7.2 Rest of APAC: Biologics Market Breakdown, by Application
11.4.7.7.3 Rest of APAC: Biologics Market Breakdown, by Source
11.4.7.7.4 Rest of APAC: Biologics Market Breakdown, by Manufacturing
11.5 Middle East and Africa
11.5.1 Middle East and Africa Biologics Market Overview
11.5.2 Middle East and Africa: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3 Middle East and Africa: Biologics Market Breakdown, by Product
11.5.3.1 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Product
11.5.4 Middle East and Africa: Biologics Market Breakdown, by Application
11.5.4.1 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Application
11.5.5 Middle East and Africa: Biologics Market Breakdown, by Source
11.5.5.1 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Source
11.5.6 Middle East and Africa: Biologics Market Breakdown, by Manufacturing
11.5.6.1 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Manufacturing
11.5.7 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Country
11.5.7.1 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Country
11.5.7.2 South Africa: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.5.7.2.1 South Africa: Biologics Market Breakdown, by Product
11.5.7.2.2 South Africa: Biologics Market Breakdown, by Application
11.5.7.2.3 South Africa: Biologics Market Breakdown, by Source
11.5.7.2.4 South Africa: Biologics Market Breakdown, by Manufacturing
11.5.7.3 Saudi Arabia: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.5.7.3.1 Saudi Arabia: Biologics Market Breakdown, by Product
11.5.7.3.2 Saudi Arabia: Biologics Market Breakdown, by Application
11.5.7.3.3 Saudi Arabia: Biologics Market Breakdown, by Source
11.5.7.3.4 Saudi Arabia: Biologics Market Breakdown, by Manufacturing
11.5.7.4 United Arab Emirates: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.5.7.4.1 United Arab Emirates: Biologics Market Breakdown, by Product
11.5.7.4.2 United Arab Emirates: Biologics Market Breakdown, by Application
11.5.7.4.3 United Arab Emirates: Biologics Market Breakdown, by Source
11.5.7.4.4 United Arab Emirates: Biologics Market Breakdown, by Manufacturing
11.5.7.5 Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.5.7.5.1 Rest of Middle East and Africa: Biologics Market Breakdown, by Product
11.5.7.5.2 Rest of Middle East and Africa: Biologics Market Breakdown, by Application
11.5.7.5.3 Rest of Middle East and Africa: Biologics Market Breakdown, by Source
11.5.7.5.4 Rest of Middle East and Africa: Biologics Market Breakdown, by Manufacturing
11.6 South and Central America
11.6.1 South and Central America Biologics Market Overview
11.6.2 South and Central America: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.6.3 South and Central America: Biologics Market Breakdown, by Product
11.6.3.1 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Product
11.6.4 South and Central America: Biologics Market Breakdown, by Application
11.6.4.1 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Application
11.6.5 South and Central America: Biologics Market Breakdown, by Source
11.6.5.1 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Source
11.6.6 South and Central America: Biologics Market Breakdown, by Manufacturing
11.6.6.1 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Manufacturing
11.6.7 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Country
11.6.7.1 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Country
11.6.7.2 Brazil: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.6.7.2.1 Brazil: Biologics Market Breakdown, by Product
11.6.7.2.2 Brazil: Biologics Market Breakdown, by Application
11.6.7.2.3 Brazil: Biologics Market Breakdown, by Source
11.6.7.2.4 Brazil: Biologics Market Breakdown, by Manufacturing
11.6.7.3 Argentina: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.6.7.3.1 Argentina: Biologics Market Breakdown, by Product
11.6.7.3.2 Argentina: Biologics Market Breakdown, by Application
11.6.7.3.3 Argentina: Biologics Market Breakdown, by Source
11.6.7.3.4 Argentina: Biologics Market Breakdown, by Manufacturing
11.6.7.4 Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.6.7.4.1 Rest of South and Central America: Biologics Market Breakdown, by Product
11.6.7.4.2 Rest of South and Central America: Biologics Market Breakdown, by Application
11.6.7.4.3 Rest of South and Central America: Biologics Market Breakdown, by Source
11.6.7.4.4 Rest of South and Central America: Biologics Market Breakdown, by Manufacturing
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies in Biologics Market
12.3 Organic Growth Strategies
12.3.1 Overview
12.4 Inorganic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 AbbVie Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Pfizer Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Samsung Biologics Co Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 WuXi Biologics Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Catalent Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 AGC Biologics AS
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 AstraZeneca Plc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Amgen Inc
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Nitto Avecia
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Quality Assistance s.a.
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
14. Appendix
14.1 About The the Reporting Teams

LIST OF TABLES

Table 1. Biologics Market Segmentation
Table 2. Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Table 3. Biologics Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 4. Biologics Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 5. Biologics Market – Revenue and Forecast to 2031 (US$ Million) – by Source
Table 6. Biologics Market – Revenue and Forecast to 2031 (US$ Million) – by Manufacturing
Table 7. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 8. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 9. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 10. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 11. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 12. United States: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 13. United States: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 14. United States: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 15. United States: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 16. Canada: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 17. Canada: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 18. Canada: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 19. Canada: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 20. Mexico: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 21. Mexico: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 22. Mexico: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 23. Mexico: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 24. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 25. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 26. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 27. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 28. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 29. Germany: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 30. Germany: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 31. Germany: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 32. Germany: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 33. United Kingdom: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 34. United Kingdom: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 35. United Kingdom: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 36. United Kingdom: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 37. Italy: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 38. Italy: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 39. Italy: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 40. Italy: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 41. France: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 42. France: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 43. France: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 44. France: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 45. Spain: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 46. Spain: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 47. Spain: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 48. Spain: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 49. Rest of Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 50. Rest of Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 51. Rest of Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 52. Rest of Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 53. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 54. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 55. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 56. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 57. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 58. China: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 59. China: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 60. China: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 61. China: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 62. India: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 63. India: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 64. India: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 65. India: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 66. Japan: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 67. Japan: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 68. Japan: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 69. Japan: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 70. South Korea: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 71. South Korea: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 72. South Korea: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 73. South Korea: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 74. Australia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 75. Australia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 76. Australia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 77. Australia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 78. Rest of APAC: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 79. Rest of APAC: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 80. Rest of APAC: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 81. Rest of APAC: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 82. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 83. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 84. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 85. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 86. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 87. South Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 88. South Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 89. South Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 90. South Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 91. Saudi Arabia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 92. Saudi Arabia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 93. Saudi Arabia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 94. Saudi Arabia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 95. United Arab Emirates: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 96. United Arab Emirates: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 97. United Arab Emirates: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 98. United Arab Emirates: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 99. Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 100. Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 101. Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 102. Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 103. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 104. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 105. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 106. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 107. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 108. Brazil: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 109. Brazil: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 110. Brazil: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 111. Brazil: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 112. Argentina: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 113. Argentina: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 114. Argentina: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 115. Argentina: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 116. Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 117. Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 118. Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 119. Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 120. Recent Organic Growth Strategies in Biologics Market
Table 121. Recent Inorganic Growth Strategies in the Biologics Market

LIST OF FIGURES

Figure 1. Biologics Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Biologics Market Revenue (US$ Million), 2021–2031
Figure 5. Biologics Market Share (%) – by Product (2023 and 2031)
Figure 6. Monoclonal Antibodies: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. Vaccine: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Recombinant Hormones/Proteins: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Cell and Gene Therapy: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Others: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Biologics Market Share (%) – by Application (2023 and 2031)
Figure 12. Cancer: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Infectious Diseases: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Autoimmune Diseases: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Others: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Biologics Market Share (%) – by Source (2023 and 2031)
Figure 17. Mammalian: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Microbial: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Biologics Market Share (%) – by Manufacturing (2023 and 2031)
Figure 20. Outsourced: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. In-house: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Biologics Market Breakdown by Region, 2023 and 2031 (%)
Figure 23. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 24. North America: Biologics Market Breakdown, by Product (2023 and 2031)
Figure 25. North America: Biologics Market Breakdown, by Application (2023 and 2031)
Figure 26. North America: Biologics Market Breakdown, by Source (2023 and 2031)
Figure 27. North America: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
Figure 28. North America: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 29. United States: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 30. Canada: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 31. Mexico: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 32. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 33. Europe: Biologics Market Breakdown, by Product (2023 and 2031)
Figure 34. Europe: Biologics Market Breakdown, by Application (2023 and 2031)
Figure 35. Europe: Biologics Market Breakdown, by Source (2023 and 2031)
Figure 36. Europe: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
Figure 37. Europe: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 38. Germany: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 39. United Kingdom: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 40. Italy: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 41. France: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 42. Spain: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 43. Rest of Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 44. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 45. Asia Pacific: Biologics Market Breakdown, by Product (2023 and 2031)
Figure 46. Asia Pacific: Biologics Market Breakdown, by Application (2023 and 2031)
Figure 47. Asia Pacific: Biologics Market Breakdown, by Source (2023 and 2031)
Figure 48. Asia Pacific: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
Figure 49. Asia Pacific: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 50. China: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 51. India: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 52. Japan: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 53. South Korea: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 54. Australia: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 55. Rest of APAC: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 56. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 57. Middle East and Africa: Biologics Market Breakdown, by Product (2023 and 2031)
Figure 58. Middle East and Africa: Biologics Market Breakdown, by Application (2023 and 2031)
Figure 59. Middle East and Africa: Biologics Market Breakdown, by Source (2023 and 2031)
Figure 60. Middle East and Africa: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
Figure 61. Middle East and Africa: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 62. South Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 63. Saudi Arabia: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 64. United Arab Emirates: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 65. Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 66. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 67. South and Central America: Biologics Market Breakdown, by Product (2023 and 2031)
Figure 68. South and Central America: Biologics Market Breakdown, by Application (2023 and 2031)
Figure 69. South and Central America: Biologics Market Breakdown, by Source (2023 and 2031)
Figure 70. South and Central America: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
Figure 71. South and Central America: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 72. Brazil: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 73. Argentina: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 74. Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 75. Growth Strategies in Biologics Market